CRISPR Therapeutics (NASDAQ: CRSP) CEO executes 10b5-1 share sales

Rhea-AI Filing Summary

CRISPR Therapeutics Chief Executive Officer and director Samarth Kulkarni reported multiple open-market sales of common shares under a pre-set Rule 10b5-1 trading plan adopted on August 27, 2025. On January 20, 2026, he sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23. Following these transactions, Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/20/2026		S(1)		21,433	D	$51.61(2)	202,768	D
Common Shares	01/20/2026		S(1)		8,567	D	$52.1(3)	194,201	D
Common Shares	01/22/2026		S(1)		60,000	D	$60.23(4)	134,201	D
Common Shares								85,622	I	The Kulkarni 2023 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.45 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did CRISPR Therapeutics (CRSP) report for Samarth Kulkarni?

CRISPR Therapeutics reported that Chief Executive Officer and director Samarth Kulkarni sold common shares of the company in several open-market transactions in January 2026.

How many CRISPR Therapeutics shares did Samarth Kulkarni sell and at what prices?

On January 20, 2026, Samarth Kulkarni sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23.

Were Samarth Kulkarni’s CRISPR Therapeutics share sales under a trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Samarth Kulkarni on August 27, 2025.

How many CRISPR Therapeutics shares does Samarth Kulkarni own after these transactions?

After the reported sales, Samarth Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.

What role does Samarth Kulkarni hold at CRISPR Therapeutics (CRSP)?

Samarth Kulkarni is reported as both a Director and the Chief Executive Officer of CRISPR Therapeutics.

What do the weighted average prices in the CRISPR Therapeutics Form 4 mean?

The filing notes that the reported prices are weighted average prices for shares sold in multiple transactions within specified price ranges on each date.

What is The Kulkarni 2023 GRAT mentioned in the CRISPR Therapeutics Form 4?

The Form 4 shows an indirect holding of 85,622 common shares attributed to The Kulkarni 2023 GRAT, indicating ownership through that grantor retained annuity trust.